Standard BioTools Gets Second Nasdaq Bid-Price Warning With Merger Pending
Merger Pending
Company Background
Standard BioTools (NASDAQ: LAB) operates mass cytometry and microfluidics instrument businesses aimed at biomedical researchers. The company completed the sale of its SomaLogic proteomics unit to Illumina for $350 million upfront (plus up to $75 million in earnouts) on January 30, 2026, leaving it with approximately $550 million in cash and a much smaller continuing revenue base — roughly $80 to $85 million annually.
The base business has been loss-making throughout this period, though improving. Revenue from continuing operations rose 5% year-over-year to $21.1 million in Q1 2026, and adjusted EBITDA loss narrowed 78% to $3.1 million. Management has guided for positive adjusted EBITDA exiting 2026, supported by restructuring actions taken in late 2025 that eliminated approximately 20% of the global workforce and are expected to deliver more than $40 million in annualized cost savings.
On June 6, 2026, Standard BioTools announced a definitive all-stock merger agreement with Treeline Biosciences, Inc., a privately held clinical-stage oncology company. Under the deal, Treeline shareholders would receive Standard BioTools stock representing an implied equity value of $2.5 billion for Treeline, while existing Standard BioTools shareholders would retain approximately 16% of the combined company. The combined entity would be renamed Treeline Biosciences Holdings, Inc. and trade on Nasdaq under the ticker "TRLN."
What Was Disclosed
A second Nasdaq deficiency notice arrived on July 22, 2026, informing the company that its common stock had closed below the $1.00 minimum bid price threshold required for continued listing on the Nasdaq Global Select Market for 30 consecutive business days. Under Nasdaq's automatic 180-day compliance period, the company has until January 19, 2027 to maintain a closing bid at or above $1.00 for at least 10 consecutive business days. The notice does not immediately affect trading or the company's SEC reporting obligations.
If the company fails to cure the deficiency by January 19, 2027, it may be eligible for an additional 180-day extension by transferring to the Nasdaq Capital Market, provided it meets that market's other listing standards and provides written notice of its intention to cure — for example, by implementing a reverse stock split. The company stated it "intends to work toward restoring compliance within the prescribed timeframe" but offered no assurance it would succeed.
Why It Matters
This is the second bid-price deficiency notice Standard BioTools has received in roughly three months. The first was issued on April 20, 2026. The company regained compliance on June 5, 2026 — one day before announcing the Treeline merger — and fell back below $1.00 within weeks. The rapid relapse illustrates that the share price weakness has been persistent.
The Treeline merger agreement intersects with this problem in two ways. First, continued Nasdaq listing is an explicit closing condition of the deal: Standard BioTools shares must be listed on Nasdaq as of the closing date. Second, the merger agreement anticipates this exact scenario: at the effective time of the merger, Standard BioTools is required to effect a reverse stock split if one has not already been completed. The deal's own mechanics are designed to resolve the bid-price deficiency. Management expects the transaction to close in the second half of 2026 — before the January 19, 2027 compliance deadline — which, if achieved on schedule, would make this notice largely moot in practical terms.
The more pointed risk is timing. If the S-4 registration statement, Standard BioTools stockholder vote, and HSR antitrust clearance take longer than anticipated, the company could approach the January 2027 deadline still below $1.00 with no merger closing imminent. In that scenario, a standalone reverse split would likely be required. Separately, Treeline disclosed at the time of the merger announcement that the FDA had placed a partial clinical hold on its TLN-254 EZH2 inhibitor program on June 2, 2026 — four days before the merger was publicly announced — pausing enrollment in both monotherapy and combination study cohorts. That setback introduces uncertainty into the clinical pipeline that investors are being asked to buy into.